May 29, 2019 Clinical Research/Diagn.

Quanterix Expands Headquarters to New, State-of-the-art Facility in Billerica, Mass. As Demand Continues to Grow for Its Disruptive Simoa Platforms

MAY 29, 2019 World-class facility will offer the Company nearly three times the space for disruptive biomarker technology innovation and to accommodate growing pharma services business Billerica, Mass. – May 29, 2019 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters... Read more

March 28, 2019 Clinical Research/Diagn. Liq. Handling & Robotics PR/Corporate

Quanterix Appoints Amol Chaubal as Chief Financial Officer

MARCH 28, 2019 Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth and scaling  LEXINGTON, Mass. – March 28, 2019 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Amol Chaubal to the position of... Read more

November 6, 2018 Clinical Research/Diagn. Product Launch

Quanterix Expanding Transformative Biomarker Technology Portfolio Into Oncology

NOVEMBER 07, 2018 Launching Test Bed for up to 10-plex assays with Simoa Sensitivity and Specificity to Advance Cancer Research Lexington, Mass. – November 7, 2018 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced an Early Access Program for the latest advance in Simoa Sensitivity assays... Read more

October 22, 2018 Clinical Research/Diagn. M&A, Partnerships

Quanterix Announces Collaboration With Oncogenesis to Develop Cervical Screening Test

OCTOBER 22, 2018 Quanterix’ technology to be used in multiplex diagnostic test for cervical disease detection Lexington, Mass. – October 22, 2018 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration agreement with OncoGenesis, a molecular protein-based cervical screening company, to develop a quantitative, protein... Read more

September 12, 2018 Clinical Research/Diagn. Licensing, IP, and Legal

Quanterix Announces Termination of License Agreement With Biomérieux

Secures and Consolidates Unrestricted Rights for Simoa Technology in Diagnostics Market LEXINGTON, Mass.–(BUSINESS WIRE)–Sep. 12, 2018– Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the consolidation of its licensing position and reestablishment of control of its intellectual property in the in vitro diagnostics (IVD) field. The termination... Read more

March 20, 2018 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection

Collaboration offers potential for PCR-free microRNA biomarker detection with high-specificity and ultra-sensitivity March 20, 2018 06:00 AM Pacific Daylight Time LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration with DestiNA Genomics, a manufacturer of patented reagents for nucleic acid detection.... Read more

August 15, 2017 Product Launch

QUANTERIX TO LAUNCH HIGH-SENSITIVITY BENCHTOP INSTRUMENT AND ASSAYS FOR MULTIPLEX BIOMARKER DETECTION

AUGUST 15, 2017 Boston, MA and Washington D.C. – August 15, 2017 — Quanterix Corporation, a company dedicated to digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it will be expanding its single molecule array, or Simoa, technology platform portfolio to include the new Quanterix SR-Plex benchtop instrument. In... Read more